After a slapdown on Orkambi price, Vertex is dropping French trial sites while warning patients on access
Vertex Pharma $VRTX is playing hardball with French drug regulators — and cystic fibrosis patients waiting for their next-gen triple are getting caught in the middle.
Mired in a long-running dispute over the reimbursement level for their drug Orkambi, Vertex has decided to shut out the trial sites it had selected in France for the late-stage combination studies for its cystic fibrosis drugs, including the experimental VX-659, which has raised hopes for a broad swath of patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
